"A randomized, double-blind, placebo-controlled phase III multi-center study of azacitidine with or without MBG453 for the treatment of patients with intermediate, high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)"

drug protocol number
CMBG453B12301
drug sponsor
Novartis
drug study
MBG453 (sabatolimab)
drug trial site
King Faisal Specialist Hospital and Research Center (Riyadh)
drug status
Ongoing
drug phase